Health Sciences Acquisitions2 (id:6563 OBIO)
5.77 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/23/2024 8:21:24 PM)
Exchange closed, opens in 1 day 13 hours
About Health Sciences Acquisitions2
Market Capitalization 206.79M
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
| Headquarters (address) |
150 Union Square Drive New Hope 18938 PA United States |
| Phone | 212 862 5797 |
| Website | https://orchestrabiomed.com |
| Employees | 56 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | OBIO |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 4.22 - 11.69 |
| Market Capitalization | 206.79M |
| P/E trailing | -3.90 |
| P/E forward | -3.09 |
| Price/Sale | 78.12 |
| Price/Book | 4.47 |
| Beta | 0.409 |
| EPS | -1.60 |
| EPS United States (ID:6, base:3403) | 24.22 |